Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders

Table 3 Prevalence of mental health alterations and lipodystrophy symptoms by gender

	Male N (%)	Female N (%)	p value
Presence of depression (BDI score ≥19)^a	28 (26.9)	40 (46.0)	0.006*
Presence of anxiety (STAI-Y-B score ≥46)^b	44 (42.7)	55 (62.5)	0.006*
Poor QoL (≤50% visual score)^c	43 (41.4)	50 (59.5)	0.013*
Severe LD (LDCD score ≥23 points)^d	21 (28.8)	10 (16.1)	0.082
HOPS score:^e
Atrophy observed by patients	66 (72.5)	40 (52.6)	0.008*
Atrophy observed by physicians	46 (60.0)	25 (37.3)	0.007*
Hypertrophy observed by patients	47 (51.1)	59 (76.6)	0.001*
Hypertrophy observed by physicians	35 (46.7)	44 (63.8)	0.039*

^aPresence of depression: according to Beck Depression Inventory score by Beck definition (BDI).
^bPresence of anxiety: according to State Trait Anxiety Inventory by Spielberger definition (STAI-Y-B).
^cQuality of Life Quantitative scale numbered 0%–100 according to the short version of EQ-5D-3L score.
^dSevere LD: according to LDCD score Lipodystrophy Case Definition by Carr et al.
^eAtrophy/Hypertrophy observed by patients/physicians: according to HOPS score by Lichtenchtein et al.
* Significant p-value <0.05.

ISSN: 1742-6405